Name : MR. B.

PAWAN
Age/Gender : 27 years / Male Ref. Doctor : GOOD HEALTH DIAGNOSTICS
Sample Type: SERUM Collected : Dec 01, 2024, 10:29 a.m. MEDID : 171329
Sample ID : 24132472 Received : Dec 01, 2024, 10:41 a.m.
Client Name : 1TSWAL1617 Reported : Dec 01, 2024, 12:41 p.m.

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Lipid Profile
Cholesterol - Total 184 mg/dL <200 : Desirable
(Method: Cholesterol Oxidase, Esterase, peroxidase)
200-239 : Borderline risk
>240 : High risk
Cholesterol - HDL 58 mg/dL < 40 : Low
(Method: Enzymatic Colorimetric)
40 - 60 : Optimal
> 60 : Desirable
Cholesterol - LDL 96.20 mg/dL < 100 : Normal
(Method: Enzymatic Colorimetric)
100 - 129 : Desirable
130 – 159 : Borderline-High
160 – 189 : High
> 190 : Very High
Cholesterol VLDL 29.80 mg/dL 7 - 40
(Method: Calculated)
Triglycerides 149 mg/dL < 150 :Normal
(Method: Lipase / Glycerol Kinase)
150–199 :Borderline-High
200–499 :High
> 500 :Very High
Cholesterol - Non-HDL 126 mg/dL < 130 Desirable
(Method: Calculated)
Total cholesterol/HDL 3.17 Ratio 0 - 5.0
(Method: Calculated)
LDL / HDL 1.66 Ratio 0 - 3.5
(Method: Calculated)
Interpretation:
• For non-fasting samples, the biological reference interval remains the same for all parameters, except of triglyceride as cholesterol (HDL, LDL, total), which

changes only by a small amount in the non-fasting state; the recommended desired value for triglyceride is <175 mg/dl. In the non-sting state,

individuals with a non-fasting triglyceride level >200 mg/dl, are recommended to perform a follow-up fasting lipid panel in 2 to 4 weeks.

• As per the consensus of the Lipid Association of India, non-HDL cholesterol and LDL cholesterol can be used as targets to monitor the effectiveness of

lipid-lowering therapy.

Associated tests: Apolipoproteins A1, Apolipoproteins B, Apolipoprotein B/A1 Ratio, Lipoprotein(a)

**END OF REPORT**

Processed At: Medcis Pathlabs Hyderabad. This is an electronically authenticated report. Report Printed Date: Dec 01, 2024, 01:37 p.m.
NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 1 of 9
 Name : MR. B.PAWAN
Age/Gender : 27 years / Male Ref. Doctor : GOOD HEALTH DIAGNOSTICS
Sample Type : Serum Collected : Dec 01, 2024, 10:29 a.m. MEDID : 171329
Sample ID : 24132472 Received : Dec 01, 2024, 10:41 a.m.
Client Name : 1TSWAL1617 Reported : Dec 01, 2024, 01:18 p.m.

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Liver Function Profile

Bilirubin Total 3.8 mg/dL 0 - 1.0
(Method: Diazo Method)
Bilirubin Direct 1.2 mg/dL 0 - 0.3
(Method: Diazo method)
Bilirubin Indirect 2.60 mg/dL 0 - 1.0
(Method: Calculated)
Alkaline Phosphatase (ALP) 152 U/L 50 - 136
(Method: PNPP, AMP Buffer)
Alanine Transaminase (ALT/SGPT) 655 U/L Upto 41
(Method: UV without pyridoxal -5- phosphate)
Aspartate Aminotransferase(AST/SGOT) 350 U/L Upto 40
(Method: IFCC Without Pyridoxal Phosphate)
Y- Glutamyl Transferase (GGT) 158 U/L 8 - 61
(Method: glutamyl-carboxynitroanilide)
Protein Total 6.7 g/dL 6.4 - 8.3
(Method: Biuret)
Albumin 3.7 g/dL 3.5 - 5.4
(Method: Bromcresol Green)
Globulin 3 g/dl 2.5 - 3.5
(Method: Calculated)
Albumin/Globulin 1.23 Ratio 1.0 - 2.1
(Method: Calculated)
Interpretation:
LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity(AST & ALT),synthesis and secretion of bile (Bilirubin ,ALP),cholestasis (ALP,GGT),protein synthesis (Albumin).
1. Hepatocellular injury:
• AST-Elevated levels can be seen. However,it is not specific to liver and can be raised in cardiac and skeletal injuries.
• ALT -Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury.
Values also correlate well with increasing BMI.
• Disproportinate increase in AST,ALT compared with ALP.
• Bilirubin may be elevated.
• AST: ALT (ratio) - In case of hepatocellular injury AST : ALT >1
In Alcoholic Liver Disease AST : ALT usually >2
This ratio is also seen to be increased in NAFLD ,Wilsons's disease, Cirrhosis ,but the increase is usually not >2
2. Cholestatic pattern:
• ALP - Disproportinate increase in ALP compared with AST,ALT.
• Bilirubin may be elevated.
• ALP elevation also seen in pregnancy,impacted by age and sex.
• To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
3. Synthesis function impairment:
• Albumin - Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time ) helps.

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: Dec 01, 2024, 01:37 p.m.
NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 2 of 9
Name : MR. B.PAWAN
Age/Gender : 27 years / Male Ref. Doctor : GOOD HEALTH DIAGNOSTICS
Sample Type : SERUM Collected : Dec 01, 2024, 10:29 a.m. MEDID : 171329
Sample ID : 24132472 Received : Dec 01, 2024, 10:41 a.m.
Client Name : 1TSWAL1617 Reported : Dec 01, 2024, 01:18 p.m.

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Creatinine 0.8 mg/dL 0.7 - 1.4

(Method: Jaffe Kinetic)
Urea 20 mg/dL Upto 50
(Method: Urease)
Blood Urea Nitrogen (BUN) 9.35 mg/dL 7 - 18
(Method: Calculated)
Blood Urea Nitrogen (BUN)/Creatinine 11.69 Ratio 6 - 22
(Method: Calculated)
Sodium 140 mmol/L 135 - 145
(Method: ISE)
Potassium 3.8 mmol/L 3.8 - 5.2
(Method: ISE)
Chloride 101 mmol/L 94 - 108
(Method: ISE)
Uric Acid 5.5 mg/dL 3.4 - 7.0
(Method: Uricase)
Glomerular Filtration Rate (eGFR) 140.54 mL/min 90 - 120 mL/min/1.73 m2
(Method: Calculated)
Interpretation:
Creatinine: Muscles produce creatinine, a waste product, from creatine phosphate, a substance that stores a lot of energy. Unlike urea, the amount of creatinine generated is
constant and mostly depends on muscle mass. Age, gender, race, muscularity, exercise, pregnancy, and several other physiulogical characteristics can all have an impact on
serum creatinine levels. Decreased serum Creatinine is associated with increasing Age and poor muscle mass, such as muscular atrophy. Both acute and chronic renal
disease and blockage are associated with elevated blood creatinine levels. Creatinine is not an appropriate indicator for identifying kidney disease in its early stages since an
increase in blood creatinine is only seen when there is significant nephron damage.
High Urea, Uric Acid, and Blood Urea Nitrogen (BUN) could indicate poor renal function, in addition to other etiulogies
Sodium:
• Low levels: prulonged vomiting or diarrhea, diminished reabsorption in the kidney, and excessive fluid retention. Pseudo-hyponatremia is a laboratory artifact. It is
usually caused by hypertriglyceridemia, chulestasis (lipoprotein X), and hyperproteinemia (monoclonal gammopathy, intravenous immunoglobulin [IVIG]). Diluted sampling
should also be suspected in such cases and confirmed on a repeat fresh sample if indicated clinically.
• High levels: excessive fluid loss, high salt intake, and increased kidney reabsorption.
Potassium:
• Low levels: reduced intake of dietary potassium or excessive loss of potassium from the body due to diarrhea, prulonged vomiting, or increased renal excretion.
• High levels: dehydration or shock, severe burns, hemulysis, diabetic ketoacidosis, and retention of potassium by the kidney. Pseudohyperkalemia, which may result
from a hemulyzed or aged sample, should always be ruled out by doing a repeat electrulyte estimation on a fresh sample, as clinically indicated.
Chloride:
• Low levels are noted in reduced dietary intake, prulonged vomiting, and reduced renal reabsorption, as well as some forms of acidosis and alkalosis.
• High levels are found in dehydration, kidney failure, some forms of acidosis, high dietary or parenteral chloride intake, and salicylate poisoning
An estimated glomerular filtration rate (eGFR) test is an indicator of how well kidneys filter waste and toxins from blood.

**END OF REPORT**

Page 3 of 9
 Name : MR. B.PAWAN
Age/Gender : 27 years / Male Ref. Doctor : GOOD HEALTH DIAGNOSTICS
Sample Type : Serum Collected : Dec 01, 2024, 10:29 a.m. MEDID : 171329
Sample ID : 24132472 Received : Dec 01, 2024, 10:41 a.m.
Client Name : 1TSWAL1617 Reported : Dec 01, 2024, 12:41 p.m.

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

IRON PROFILE
Iron 126 µg/dL 33 - 193
(Method: Ferrozine – without Deproteinization)
Iron Binding Capacity - Total (TIBC) 291 µg/dL 240 - 450
(Method: Calculated)
Transferrin 197.96 ug/dL 176 - 280
(Method: Immunoturbidimetry)
Transferrin % 43.30 % 20 - 50
(Method: Calculated)

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: Dec 01, 2024, 01:37 p.m.
NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 4 of 9
 Name : MR. B.PAWAN
Age/Gender : 27 years / Male Ref. Doctor : GOOD HEALTH DIAGNOSTICS
Sample Type : Serum Collected : Dec 01, 2024, 10:29 a.m. MEDID : 171329
Sample ID : 24132472 Received : Dec 01, 2024, 10:41 a.m.
Client Name : 1TSWAL1617 Reported : Dec 01, 2024, 11:56 a.m.

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Thyroid Profile-II
Triiodothyronine Total (TT3) 141.6 ng/dL 80 – 253: 1 Yr – 10 Yr
(Method: CLIA)
76 – 199: 11 Yr – 15 Yr
69 – 201: 16 Yr – 18 Yr
60 – 181 : > 18 years
Triiodothyronine Free (FT3) 2.96 pg/mL 2.3 - 4.2
(Method: CLIA)
Thyroxine - Total (TT4) 9.15 ug/dL 4.6 - 12.5
(Method: CLIA)
Thyroxine - Free (FT4) 1.36 ng/dL 0.80-2.70
(Method: CLIA)
Thyroid Stimulating Hormone (TSH) 0.48 uIU/mL 0.52-16.0: 1 Day - 30 Days
(Method: CLIA)
0.55–7.10: 1 Mon – 5 Yrs
0.37–6.00: 6 Yrs – 18 Yrs
0.35–5.50: 18 Yrs – 55 Yrs
0.50–8.90 : > 55 yrs
Interpretation:
Important Note:

A TSH value of up to 15 µIU/ml needs clinical correlation or repeat testing with a new sample, as physiological factors can give falsely high TSH.

Transiently Raised TSH can occur due to non-thyroid illnesses like severe infections liver, cardiac, and kidney diseases, burns, surgery, and trauma.

Diurnal Variability: TSH Follows a Diurinal rhythm and is at maximum between 2 am to 4 am and a minimum between 6 to 10 pm. Variation is about

50-206%.

Limitations:
• Patients receiving High Biotin Dose treatment should have a gap of a minimum of 8 hrs, before giving the blood sample.
• Heterophile Antibodies can react in Immunoassay procedures giving erroneous results. The assay is designed to minimize heterophile antibody
interference.
Please Note: FT3 and FT4 Measure the free "unbound" fraction of the T3 and T4 and are considered more sensitive compared to the Total T3 and T4 to

assess thyroid status.

Associated tests: Anti-thyroid Antibodies, USG thyroid, TSH receptor Antibody. Thyroglobulin, Calcitonin.

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: Dec 01, 2024, 01:37 p.m.
NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 5 of 9
 Name : MR. B.PAWAN
Age/Gender : 27 years / Male Ref. Doctor : GOOD HEALTH DIAGNOSTICS
Sample Type : Wb Edta Collected : Dec 01, 2024, 10:29 a.m. MEDID : 171329
Sample ID : 24132471 Received : Dec 01, 2024, 10:41 a.m.
Client Name : 1TSWAL1617 Reported : Dec 01, 2024, 11:55 a.m.

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS REFERENCE RANGES

Glycosylated Hemoglobin (GHb/HBA1c)

HbA1c 5.7 % < 6.0 : Non Diabetic
(Method: HPLC)
6.1 – 6.5 : Prediabetic
6.6 – 7.0 : Good Control
7.1-8.0 : POOR Control
>8.1 : ALERT
Estimated Average Glucose (eAG) 116.89 % 70 - 136
Interpretation:
• HbA1c, also known as glycosylated hemoglobin or glycated hemoglobin, refers to hemoglobin that has glucose molecules attached. It gives an
average of glucose levels in the bloodstream for the preceding 2 to 3 months.
• HbA1c has been endorsed by clinical groups & ADA (American Diabetes Association) guidelines for the diagnosis of diabetes using a cut-off point of
6.5%.
• For diabetic patients achieving treatment objectives, the HbA1c test should be conducted at least biannually. If treatment objectives are not met or if
a new regimen is initiated, testing once every 3 months is recommended.
• The HbA1c target for non-pregnant adults is generally set at below 7% to prevent microvascular complications.
• In known diabetic patients, the following values can be considered as a tool for monitoring glycemic control.
Excellent Control: 6 to 7 %
Fair to Good Control: 7 to 8 %
Unsatisfactory Control: 8 to 10 %
and Poor Control: More than 10%.
Factors Influencing HbA1c Results: Increased levels: Elevated fetal hemoglobin, chronic renal failure, iron deficiency anemia, splenectomy,
heightened serum triglycerides, alcohol consumption, poisoning (Lead, Opiate), and salicylate therapy. Decreased levels: are often associated with
systemic inflammatory diseases and reduced RBC life span, severe iron deficiency & haemolytic anaemia, chronic renal failure, and liver diseases.
Clinical correlation reduced red blood cell lifespan (such as in hemolytic anemia or blood loss), following blood transfusions, during pregnancy,
excessive intake of Vitamin E or Vitamin C, and hemoglobinopathies, For HbF > 25% and homozygous hemoglobinopathy, an alternate platform
(Fructosamine) is recommended for testing of HbA1c.
• Kindly Repeat the HbA1c test, and Correlate it with other findings (Fasting, Urine Glucose). Please repeat the test with a fresh sample,
if indicated clinically.
Associated tests: HOMA IR index, insulin, C-peptide levels.

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: Dec 01, 2024, 01:37 p.m.
NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 6 of 9
Name : MR. B.PAWAN
Age/Gender : 27 years / Male Ref. Doctor : GOOD HEALTH DIAGNOSTICS
Sample Type : WB EDTA Collected : Dec 01, 2024, 10:29 a.m. MEDID : 171329
Sample ID : 24132471 Received : Dec 01, 2024, 10:41 a.m.
Client Name : 1TSWAL1617 Reported : Dec 01, 2024, 12:41 p.m.

HAEMATOLOGY

TEST DESCRIPTION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Complete Blood Count + ESR

Hemoglobin (Hb) 16.0 g/dL 13.0 - 17.0
(Method: Photometry)
Erythrocyte Count (RBC Count) 5.5 mil/µL 4.5 - 5.5
(Method: Electronic Impedance)
PCV (Hematocrit) 48.7 % 40 - 50
(Method: Calculated)
Platelet Count 2.82 lakh/Cumm 1.5 - 4.0
(Method: Electronic Impedance)
MCV 87.9 fl 83 - 101
MCH 28.9 pg 27 - 32
MCHC 32.8 g/dL 31.5 - 34.5
RDW - CV 14.3 % 11.5 - 14.5
WBC Count 9410 cells/Cumm 4000 - 11000
Neutrophils 63 % 40 - 80
Lymphocytes 25 % 20 - 40
Eosinophils 03 % 1-6
Monocytes 09 % 2 - 10
Basophils 00 % 0-1
Erythrocyte Sedimentation Rate (ESR) 08 mm/Hour < 10
(Method: Westergren's)

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: Dec 01, 2024, 01:37 p.m.
NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 7 of 9
Name : MR. B.PAWAN
Age/Gender : 27 years / Male Ref. Doctor : GOOD HEALTH DIAGNOSTICS
Sample Type : SERUM Collected : Dec 01, 2024, 10:29 a.m. MEDID : 171329
Sample ID : 24132472 Received : Dec 01, 2024, 10:41 a.m.
Client Name : 1TSWAL1617 Reported : Dec 01, 2024, 12:41 p.m.

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Calcium & Phosphorus

Calcium 9.3 mg/dL 8.6 - 10.3
(Method: NM-Bapta complex)
Interpretation:
The diagnosis and monitoring of a wide range of disorders including diseases of bone, kidney, parathyroid gland, or gastrointestinal tract
Calcium levels may also reflect abnormal vitamin D or protein levels. Calcium ions affect the contractility of the heart and the skeletal
musculature, and are essential for the function of the nervous system. In addition, calcium ions play an important role in blood clotting and
bone mineralization.
Hypocalcemia is due to the absence or impaired function of the parathyroid glands or impaired vitamin-D synthesis. Chronic renal failure is
also frequently associated with hypocalcemia due to decreased vitamin-D synthesis as well as hyperphosphatemia and skeletal resistance to
the action of parathyroid hormone (PTH). A characteristic symptom of hypocalcemia is latent or manifest tetany and osteomalacia.

Phosphorus 2.8 mg/dL 2.5 - 4.5

(Method: Phosphomolybdate - UV)

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: Dec 01, 2024, 01:37 p.m.
NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 8 of 9
Name : MR. B.PAWAN
Age/Gender : 27 years / Male Ref. Doctor : GOOD HEALTH DIAGNOSTICS
Sample Type: SERUM Collected : Dec 01, 2024, 10:29 a.m. MEDID : 171329
Sample ID : 24132472 Received : Dec 01, 2024, 10:41 a.m.
Client Name : 1TSWAL1617 Reported : Dec 01, 2024, 11:55 a.m.

CLINICAL BIOCHEMISTRY

TEST DESCRIPTION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Folic Acid, Vitamin - B12 & 25-Hydroxy Vitamin D Total (D2 & D3)

Folate Serum (Folic Acid) 13.9 ng/mL 4 - 11 Years: 8.6 - 37.7

(Method: CLIA)
12 -19 Years: 5.0 - 27.2
20 - 59 Years: 4.4 - 31.0
>60 Years: 5.6 - 45.8

Vitamin - B12 437.2 pg/mL 197 - 771

(Method: CLIA)

25-Hydroxy Vitamin D Total (D2 & D3) 19.88 ng/mL 20 - 51

(Method: CLIA)

Interpretation:
VALUE CONDITION INFERENCE

< 10 SEVERE DEFICIENCY Could be associated with osteomalacia or rickets

10 - 19 MILD DEFICIENCY May be associated with increased risk of osteoporosis or secondary hyperparathyroidism

Optimum levels in the healthy population; patients with bone disease may benefit from higher levels
20 - 50 OPTIMUM LEVELS
within this range

INCREASED Sustained levels >50 ng/mL25OH-VitD along with prolonged calcium supplementationmay lead to
51 - 80
Risk of hypercalciuria hypercalciuria and decreased renal function

80 ng/mL is the lowest reported level associated with toxicity in patients without primary

hyperparathyroidism who have normal renal function. Most patients with toxicity have levels > 150
>80 TOXICITY POSSIBLE
ng/mL. Patients with renal failure can have very high 25-OH-VitD levels without any signs of toxicity, as

renal conversion to the active hormone 1, 25-OH-VitD is impaired or absent.

These reference ranges represent clinical decision values, based on the 2011 Institute of Medicine report, that apply to males and females of all ages, rather than

population-based reference values. Population reference ranges for 25-OH-VitD vary widely depending on ethnic background, age, geographic location of the studied

populations, and the sampling season.

**END OF REPORT**

This is an electronically authenticated report. Report Printed Date: Dec 01, 2024, 01:37 p.m.
NOTE: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.

Page 9 of 9